If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G 2N2, CanadaDepartment of Radiology, University Hospital, LMU Munich, Munich 81377, Germany
Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G 2N2, CanadaDepartment of Medical Imaging, Clinica Santa Maria, Universidad de los Andes, Santa Maria 500, Santiago, Chile 7520378
Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada
Department of Laboratory Medicine & Pathobiology, University of Toronto, 585 University Avenue, Toronto, ON M5G 2N2, CanadaLaboratory Medicine Program, University Health Network, 200 Elizabeth Street, 11E-444, Toronto, Ontario M5G 2C4, Canada
Department of Laboratory Medicine & Pathobiology, University of Toronto, 585 University Avenue, Toronto, ON M5G 2N2, CanadaLaboratory Medicine Program, University Health Network, 200 Elizabeth Street, 11E-444, Toronto, Ontario M5G 2C4, Canada
Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G 2N2, CanadaDivision of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network (UHN), University of Toronto, 4N-490, 585 University Avenue, Toronto, Ontario M5G2N2, Canada
Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network (UHN), University of Toronto, 4N-490, 585 University Avenue, Toronto, Ontario M5G2N2, CanadaCardiovascular Division, Women’s College Hospital, University of Toronto, 76 Grenville Street, Room 6324, Toronto, Ontario M5G2N2, Canada
Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G 2N2, CanadaDivision of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network (UHN), University of Toronto, 5N-517, 585 University Avenue, Toronto, Ontario M5G2N2, Canada
Corresponding author. Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G2N2, Canada.
Affiliations
Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, 1 PMB-298, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada
Myocarditis following messenger RNA–based COVID-19 vaccines is rare; however, adolescent and young adult men are at highest risk.
•
Chest pain is the most common symptom, with typical onset within a few days of vaccine administration.
•
Cardiac MRI plays an important role in the diagnosis of acute myocarditis following vaccination, with typical findings of subepicardial late gadolinium enhancement and co-localizing edema at the basal inferior lateral wall.
•
The disease course of myocarditis following COVID-19 vaccination is typically transient and mild, with resolution of symptoms within 1 to 3 weeks in most patients.
•
However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination.
Following the discovery of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019, there has been intense focus on the development of vaccines to limit the contagion and severity of coronavirus disease 2019 (COVID-19). On December 11, 2020, the US Food and Drug Administration (FDA) issued emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine (BNT162b2 mRNA). Since then, the FDA has approved the Pfizer-BioNTech COVID-19 vaccine and has authorized 2 other vaccines for emergency use, Moderna (mRNA-1273) and Janssen/Johnson & Johnson (Ad26.COV2.S). The Janssen/Johnson & Johnson vaccine is an adenovirus vector vaccine, whereas the other 2 are messenger RNA (mRNA) vaccines. As of April 2022, more than 11.5 billion COVID-19 vaccine doses have been administered worldwide.
Several side effects have been reported after administration of COVID-19 vaccines, most of which are mild and self-limited. These side effects include pain at the injection site, lymphadenopathy ipsilateral to the site of injection, fever, chills, myalgias, headache, and fatigue.
Serious side effects have been reported in a very small proportion of individuals following COVID-19 vaccination, which include thrombosis with thrombocytopenia syndrome following administration of viral vector vaccines and myocarditis and pericarditis following administration of mRNA-based vaccines.
Myocarditis is an inflammatory disease of the myocardium without an ischemic cause, which can be diagnosed by histologic, immunologic, and imaging criteria.
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the european society of cardiology working group on myocardial and pericardial diseases.
Pericarditis refers to nonischemic inflammation of the pericardium. The term myopericarditis is used when both the myocardium and pericardium are inflamed. Myocarditis following vaccination had been described very rarely before the introduction of COVID-19 vaccines, including following smallpox and anthrax vaccines.
Although rare, there has been intense interest in myocarditis following COVID-19 vaccination, particularly given the higher incidence of this adverse event in young men and concerns about the potential for long-term sequelae.
The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical presentation, imaging findings, proposed pathophysiologic mechanisms, treatment, and prognosis.
Definition of Vaccine-Associated Myocarditis
There is no test or investigation that can establish causality for vaccine-associated myocarditis or pericarditis. These associations are based on a close temporal relationship between vaccine administration and the onset of symptoms, usually defined as within 14 days although ranges of up to a month have been reported in the literature.
The US Centers of Disease Control and Prevention (CDC) has established case definitions of acute myocarditis and pericarditis, including probable or confirmed acute myocarditis and probable acute pericarditis, summarized in Table 1.
Table 1Centers for Disease Control and Prevention working case definitions for acute myocarditis and acute pericarditis
Adapted from Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977–982; and from Bozkurt B., Kamat I. and Hotez P.J., Myocarditis with COVID-19 mRNA vaccines, Circulation, 144 (6), 2021, 471–484.
CDC Working Case Definitions
Acute Myocarditis
Acute Pericarditis
Confirmed Case
Probable Case
Probable Case
Presence of ≥ 1 new or worsening of the following clinical symptoms
Clinical symptoms are for adolescents and adults. Infants and children younger than 12 years night instead have greater than or equal to 2 of the following symptoms: irritability, vomiting, poor feeding, tachypnea, and lethargy. Individuals who lack the listed symptoms but who meet other criteria may be classified as subclinical myocarditis (probable or confirmed).
•
Chest pain/pressure/discomfort
•
Dyspnea/shortness of breath
•
Palpitations
•
Syncope
AND
≥ 1 of the following
•
Histopathologic confirmation of myocarditis
•
Elevated troponin greater than upper limit of normal and CMR findings consistent with myocarditis
Clinical symptoms are for adolescents and adults. Infants and children younger than 12 years night instead have greater than or equal to 2 of the following symptoms: irritability, vomiting, poor feeding, tachypnea, and lethargy. Individuals who lack the listed symptoms but who meet other criteria may be classified as subclinical myocarditis (probable or confirmed).
To meet the ECG or rhythm monitoring criterion, a probable case must include at least one of the following: (1) ST-segment or T-wave abnormailities; (2) paroxysmal or sustained atrail, superventricular, or ventricular arrhythmias; or (3) AV nodal conduction delays or intraventricular conduction defects.
•
Abnormal function or wall motion abnormality on echocardiography
No other identifiable cause of the symptoms and findings
Presence of ≥ 2 new or worsening of the following clinical symptoms
•
Acute chest pain (typically described as pain made worse by lying down, deep inspiration, cough, and relieved by sitting up or leaning forward, although other types of chest pain may occur)
•
Pericarditis rub on examination
•
New ST-elevation or PR-depression on ECG
•
New or worsening pericardial effusion on echocardiogram or CMR
OR
•
Autopsy cases may be classified as pericarditis based on meeting histopathologic criteria of the pericardium
a Clinical symptoms are for adolescents and adults. Infants and children younger than 12 years night instead have greater than or equal to 2 of the following symptoms: irritability, vomiting, poor feeding, tachypnea, and lethargy. Individuals who lack the listed symptoms but who meet other criteria may be classified as subclinical myocarditis (probable or confirmed).
b Using the Lake Lousie criteria.
c To meet the ECG or rhythm monitoring criterion, a probable case must include at least one of the following: (1) ST-segment or T-wave abnormailities; (2) paroxysmal or sustained atrail, superventricular, or ventricular arrhythmias; or (3) AV nodal conduction delays or intraventricular conduction defects.
In the United States, most of the data on the incidence of adverse events following vaccination have been gleaned from the Vaccine Adverse Events Reporting System (VAERS). As of January 7, 2022, VAERS had received 2478 reports of myocarditis and 1900 reports of pericarditis following COVID-19 vaccination.
United States Department of Health and Human Services (DHHS) Public health service (PHS), centers for disease control (CDC)/food and Drug administration (FDA), vaccine adverse event reporting system (VAERS) 1990 - 01/07/2022.
Of note, the VAERS is a passive adverse event reporting system with limitations including reporting bias.
Postvaccine myocarditis has been documented worldwide, with no clear identified pattern of increased prevalence based on geographic region. Reported rates from different health care organizations across the world are similar, including large population-based studies from Israel and California.
Compared with COVID-19 vaccines, the incidence of myopericarditis was higher following vaccination for small pox (132 per million vaccine doses) and did not differ significantly with the incidence of myopericarditis following influenza vaccination (1.3 per million vaccine dose) or other non-small pox vaccination (57 per million vaccine doses).
The risk of myocarditis associated with mRNA-based COVID-19 vaccination is highest in men between 12 and 29 years of age following administration of the second dose.
As of June 2021, crude reporting rates of myocarditis following COVID-19 vaccination based on VAERS data were 40.6 cases per million second doses among men aged 12 to 29 years and 4.2 cases per million second doses among women aged 12 to 29 years.
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, june 2021.
The striking sex difference in adolescents and young adults has led to proposed pathophysiologic mechanisms related to sex hormones and has raised questions about the potential for underdiagnosis of myocarditis in women compared with men.
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, june 2021.
As of December 19, 2021, reported rates of myocarditis based on VAERS data per 1 million doses of Pfizer-BioNTech COVID-19 vaccines administered were only 4 for men aged 5 to 11 years compared with 46 for men aged 12 to 15 years and 70 for men aged 16 to 17 years after the second dose. For women, rates were 2, 4, and 8 in the same age ranges, respectively.
COVID-19 vaccine safety updates: primary series in children and adolescents ages 5–11 and 12–15 years, and booster doses in adolescents ages 16–24 years 2022.
The vaccine formulation of the Pfizer mRNA vaccine for ages 5 to 11 years of age is one-third the dose of the formulation for those aged 12 years and older, which raises the possibility of a weight-based dose–response relationship in younger adolescents who have lower body weight compared with adults.
Risk with different vaccinations
Among mRNA-based COVID-19 vaccines, the risk of myocarditis is higher following the Moderna vaccine compared with the Pfizer-BioNTech COVID-19 vaccine, although absolute cases numbers vary depending on local availability of each vaccine.
A study of more than 2.5 million people who received the Pfizer-BioNTech COVID-19 vaccine demonstrated an estimated incidence of myocarditis of 2.1 cases per 100,000 persons,
A large population-based study in Denmark found that the rates of myocarditis among individuals aged 12 to 39 years were 1.6 per 100,000 individuals for Pfizer-BioNTech and 5.7 per 100,000 individuals for Moderna.
Myocarditis is much more common following the second dose compared with the first but has also been reported following the first dose particularly in those with a prior history of COVID-19 infection.
However, the risk of recurrence of myocarditis following receipt of additional doses of mRNA COVID-19 vaccines in individuals with a history of confirmed myocarditis is currently unknown.
One preprint article suggests that the risk of myocarditis among individuals who received the Moderna vaccine for the second dose was higher for those who had a heterologous as opposed to homologous vaccine schedule (ie, higher in those who had received a COVID-19 vaccine other than the Moderna vaccine for their first dose).
Infection with SARS-CoV-2 can also result in myocardial inflammation, which is associated with adverse outcomes in hospitalized patients, and should be balanced against the risk of vaccine-related complications.
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, june 2021.
Data from the largest integrated health care organization in Israel indicate that SARS-CoV-2 infection is associated with an excess risk of myocarditis when compared with age- and risk-matched controls (risk ratio 18.3 and risk difference 11.0 events per 100,000 persons) that is much higher than the excess risk of myocarditis following administration of Pfizer-BioNTech COVID-19 vaccine (risk ratio 3.2 and risk difference 2.7 events per 100,000 persons).
Similarly, higher risk of myocarditis after SARS-CoV-2 infection compared with COVID-19 vaccination was recently demonstrated in a study in England that evaluated more than 38 million individuals aged 16 years and older who had received at least one dose of a COVID-19 vaccine.
The extent of abnormalities on cardiac MRI (CMR) is also less severe in myocarditis following COVID-19 vaccination compared with myocarditis following SARS-CoV-2 infection.
The clinical presentation of myocarditis following COVID-19 vaccination is similar to that of myocarditis due to other causes (see Table 1). Chest pain is the most frequently reported presenting symptom.
However, as with myocarditis from other causes, myocarditis following COVID-19 vaccination can present with variable symptoms ranging from subclinical presentations to acute arrythmia, heart failure, or rarely cardiogenic shock.
Most patients with myocarditis following COVID-19 vaccination demonstrate symptom onset within the first week after vaccination, with the vast majority presenting within the first 4 days
United States Department of Health and Human Services (DHHS) Public health service (PHS), centers for disease control (CDC)/food and Drug administration (FDA), vaccine adverse event reporting system (VAERS) 1990 - 01/07/2022.
Endomyocardial biopsy is not frequently performed in the setting of acute myocarditis but is indicated in patients with suspected myocarditis when diagnostic confirmation will alter therapy, in cases of hemodynamic instability or with clinical deterioration despite supportive care.
2011 Consensus statement on endomyocardial biopsy from the association for european cardiovascular pathology and the society for cardiovascular pathology.
A negative endomyocardial biopsy does not exclude the diagnosis of myocarditis, given sampling imprecision associated with spatial heterogeneity (patchiness) of the disease.
2011 Consensus statement on endomyocardial biopsy from the association for european cardiovascular pathology and the society for cardiovascular pathology.
However, it should also be noted that cardiac dysfunction mimicking myocarditis may result from a systemic increase in cytokine production, which does not have a histological correlate.
There are very few reports of histologically documented myocarditis following COVID-19 vaccination in the literature to date. Lymphocytic myocarditis is the predominant pattern observed in biopsied and autopsied hearts and occurs most frequently in adolescents and young adult men who present with mild, self-limited disease.
Depending on the timing of histologic assessment, a pattern of healing myocarditis may be present. Ameratunga and colleagues report a 57-year-old woman who died of fulminant necrotizing eosinophilic myocarditis 3 days after a first dose of the Pfizer-BioNTech COVID-19 vaccine.
First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the pfizer-biontech mRNA COVID-19 vaccine (BNT162b2, Comirnaty): an extremely rare idiosyncratic hypersensitivity reaction.
Interestingly, myocarditis following other viral vaccines, such as smallpox, measles-mumps-rubella, varicella, oral polio, yellow fever, influenza, hepatitis A and B, and human papillomavirus, is usually of the eosinophilic pattern, albeit not typically necrotizing.
Different histologic patterns of myocarditis are summarized in Fig. 1.
Fig. 1Examples of different histologic patterns of vaccine-associated myocarditis. (A) Lymphocytic myocarditis, the most common pattern reported in COVID-19 vaccination–associated myocarditis, is characterized by a dense mononuclear infiltrate and associated myocyte damage. (B) Healing myocarditis is more typically characterized by a loose and more mixed inflammatory infiltrate and with underlying damage already entering stages of repair (matrix formation). (C) Eosinophilic myocarditis, the pattern typically associated with other vaccinations, is characterized by a patchy infiltrate of eosinophils with relatively little cardiomyocyte damage. All images are hematoxylin and eosin (H&E)-stained slides, digital image capture (Leica DM2500 microscope, 200x original magnification with 10x Plan ocular and 20x FluorTar objective, OMAX 18MP camera, Toupview software, post-processing in GNU Image Manipulator Program 2.0); scale bar as indicated (100 μm).
Most of them focus on humoral (antibody-mediated) immunity, which is in keeping with the increased prevalence of myocarditis following the second dose of COVID-19 vaccines. One hypothesis involves molecular mimicry between the mRNA vaccine–encoded SARS-CoV2 spike glycoprotein and self-antigens in individuals with preexisting immune dysregulation, leading to polyclonal B-cell expansion, immune complex formation, and inflammation. Alternate explanations involve binding of mRNA vaccine–encoded viral spike glycoprotein to the surface of cardiomyocytes via angiotensin-converting enzyme 2 (ACE2) receptors or deposited immune complexes, thus directly acting as an antigenic trigger for inflammation. Yet another hypothesis involves production of antibodies targeting the antispike protein antibodies (ie, antiantibodies), which mimic the spike protein, bind cardiac ACE2 receptors, form immune complexes, and activate the classic complement pathway. Humoral mechanisms, however, fail to explain the case of a 40-year-old man with biopsy-proven lymphocytic myocarditis in the absence of serum SARS-CoV2 neutralizing antibodies 6 days after receiving a first dose of the Pfizer-BioNTech mRNA COVID-19 vaccine.
Consequently, a subset of postvaccine myocarditis might be caused by an innate inflammatory response to the mRNA-encoded viral spike glycoprotein. Testosterone could play a role in the inhibition of antiinflammatory cells or the stimulation of immune responses mediated by Th1 lymphocytes.
Fig. 2Potential mechanisms of myocarditis following COVID-19 mRNA vaccination. Overview of the potential mechanisms of myocarditis related to mRNA-based COVID-19 vaccination. ACE, angiotensin-converting enzyme; Th1, helper T cell. Created with BioRender.com.
Two additional mechanisms not described in the literature still warrant consideration. Theoretically, vaccine mRNA can enter circulation, rather than being directly expressed at the injection site, and could become expressed in cardiomyocytes and thus trigger direct cell-mediated responses against spike protein.
In addition, despite chemical modifications and liposome delivery to prevent such, exogenous RNA can trigger the innate immune response, causing activation of the cellular inflammasome and acting as an adjuvant to antigen-mediated responses.
A summary of diagnostic test findings in acute myocarditis is provided in Table 2. Cardiac imaging plays an important role in establishing a diagnosis of myocarditis and pericarditis, excluding other potential causes of symptoms, and risk-stratifying patients.
Table 2Diagnostic test findings in acute myocarditis
Test
Typical Findings
Strengths
Limitations
Cardiac Imaging
CMR
•
Typically evaluated using the revised Lake Louise criteria
•
T2-based criteria for myocardial edema include high native T2 and regional T2 hyperintensity
•
T1-based criteria for myocardial injury include high native T1, high ECV, and nonischemic pattern LGE
•
+/− Impaired regional and global ventricular function
•
+/− Pericardial effusion, edema, and enhancement
•
High diagnostic sensitivity and specificity for acute myocarditis
•
Useful in ruling out other potential diagnoses, such as stress-induced cardiomyopathy
•
Useful in risk stratification
•
Useful to demonstrate resolution of edema at follow-up
•
Limited availability
•
Relatively long examination time
Echocardiography
•
Impaired regional and global ventricular function
•
Pericardial effusion
•
+/− Focal echogenicity
•
+/− Left ventricular dilatation
•
+/− Impaired strain
•
Widely available
•
Relatively low cost
•
Relatively short examination time
•
Low sensitivity and specificity for myocarditis
•
Operator dependent
Cardiac CT
•
Pericardial effusion or thickening
•
+/− Myocardial wall thickening
•
Late iodine enhancement
•
Useful in ruling out other potential diagnoses that might present similarly, such as stress-induced cardiomyopathy
Transthoracic echocardiography is often the first cardiac imaging modality performed in the setting of suspected myocarditis, allowing for assessment of cardiac size and function and associated findings including the presence of a pericardial effusion. Although most findings in the setting of myocarditis are not specific, focal echogenicity, particularly in the lateral and inferior wall, and the presence of pericardial effusions have been shown to be sensitive for acute myopericarditis in young adults.
Cardiac computed tomography (CT) is infrequently used in the evaluation of suspected myocarditis but can be helpful in excluding other potential causes of acute chest pain, including obstructive coronary artery disease. In the setting of an inability to perform CMR, late iodine enhancement on CT could be considered, given high sensitivity and positive predictive value for acute myocarditis.
Cardiac fluorodeoxyglucose PET (FDG-PET) is useful in the evaluation of cardiac inflammation and is most often used clinically in the setting of cardiac sarcoidosis.
However, focal cardiac FDG uptake on PET has also been described in the setting of myocardial inflammation due to other causes including COVID-19 infection.
Combined cardiac fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging assessment of myocardial injury in patients who recently recovered from COVID-19.
Combined cardiac PET/MR adds complementary information and increases the sensitivity for mild or borderline myocarditis compared with CMR, although not widely available.
Combined cardiac fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging assessment of myocardial injury in patients who recently recovered from COVID-19.
CMR is the most important imaging modality for diagnosis of acute myocarditis. The Lake Louise criteria are most commonly used for evaluation of suspected myocarditis on CMR. These criteria were initially established in 2009 and were revised in 2018 to incorporate parametric mapping.
The revised criteria indicate a high likelihood of nonischemic myocardial inflammation when at least one of each of the T1- and T2-based criteria are met. T1-based criteria include increased native T1, increased extracellular volume (ECV), or presence of nonischemic pattern late gadolinium enhancement (LGE). T2-based criteria include increased native T2, regional T2 hyperintensity, or increased myocardial T2 signal intensity ratio compared with skeletal muscle on T2-weighted imaging. Regional and global left ventricular dysfunction and findings associated with pericarditis (including presence of a pericardial effusion and pericardial enhancement) are supportive criteria but are not required.
Although the presence of both T1- and T2-based criteria is associated with the highest specificity for active myocardial inflammation, the presence of only one criterion could still be consistent with a diagnosis of myocarditis, particularly if imaging was delayed after symptom onset or performed after immunosuppressive treatment is started (in which case edema might no longer be detectable).
Given the importance of establishing a diagnosis of myocarditis, CMR should ideally be performed as soon as possible after the onset of symptoms; this may be particularly relevant in the setting of myocarditis following COVID-19 vaccination, given reports of very rapid resolution of symptoms and the potential implications of a diagnosis on recommendations for future vaccination.
In acute myocarditis in general, LGE most commonly occurs in a subepicardial pattern and is often located at the basal inferior lateral wall. Mid-wall and septal patterns of LGE are less common but are associated with a worse prognosis.
However, isolated LGE without edema often reflects fibrosis, which is a risk marker for major cardiac events including sudden cardiac death and heart failure.
Native T1, T2, and ECV allow for quantification of myocardial tissue changes and are all elevated in the setting of myocardial edema. On the other hand, elevation of T1 and ECV in the setting of normal T2 values suggests healed myocarditis with fibrosis but no active edema.
The pattern of CMR findings in myocarditis following COVID-19 vaccination is similar to myocarditis due to other causes, although the extent and severity of abnormalities tends to be milder.
Typical findings in the acute phase include subepicardial LGE and co-localizing edema at the basal to mid-inferolateral wall, Fig. 3. Compared with other causes of myocarditis, patients with vaccine-associated myocarditis have higher left ventricular ejection fraction, less extensive LGE, and less frequent involvement of the septum.
Fig. 3COVID-19 vaccine–associated myocarditis. Short-axis 1.5 T MRI images of a young adult man with myocarditis following mRNA COVID-19 vaccine administration demonstrating (A) subepicardial late gadolinium enhancement (LGE) at the basal to mid-inferior lateral wall (red arrows), with corresponding (B) hyperintensity on T2-weighted imaging (orange arrows), (C) abnormal high native T1 (1274 ms, maximum region of interest), and (D) abnormal high native T2 (65 ms, maximum region of interest).
Follow-up CMR is often performed 3 to 6 months after acute myocarditis to evaluate for recovery of left ventricular function, resolution of edema, and any residual scarring, although there are no established guidelines defining the optimal timing of follow-up imaging.
In a case series of 13 adults with acute myocarditis following COVID-19 vaccination, intermediate-term follow-up CMR at a median of 5 months demonstrated resolution of myocardial edema, normalization of left ventricular function, and interval decrease in LGE extent (Fig. 4).
However, minimal residual LGE without edema was present in 8 out of 13 patients at follow-up, likely reflecting myocardial fibrosis. Similarly, in a case series of 16 pediatric patients with myocarditis following COVID-19 vaccination, follow-up CMR at a median of 3 months demonstrated normalization of LVEF and interval decrease in LGE extent.
However, minimal LGE persisted in 11 out of 16 and global longitudinal strain remained impaired in 12 out of 16. Longer-term follow-up in larger cohorts of patients is needed to understand the sequelae of myocarditis following vaccination and the ability of imaging abnormalities to identify patients who are at risk of adverse cardiac events.
Fig. 4Baseline and follow-up CMR in COVID-19 vaccine–associated myocarditis. Short-axis cardiac MRI images in a young adult man with myocarditis following the second dose of mRNA-1273. Baseline MRI at 1.5 T demonstrates subepicardial late gadolinium enhancement (LGE) at the basal inferior and inferolateral wall (red arrows) with corresponding high T2 signal in keeping with edema (yellow arrows), high regional native T1 (green arrows), and high regional T2 (blue arrows). Follow-up cardiac MRI performed 4 months later at 3 T demonstrates interval decrease in LGE extent (orange arrow) with resolution of edema and normalization of T1 and T2 values.
Other diagnostic investigations used frequently in the setting of myocarditis and pericarditis include electrocardiography (ECG) and assessment of cardiac blood biomarkers. ECG findings in myocarditis are nonspecific but can include ST-segment elevation, T-wave inversions, and ectopic beats.
Although these findings have low sensitivity for myocarditis, ECG is frequently used in patients with suspected myocarditis to evaluate for alternative causes of cardiac symptoms.
In the setting of pericarditis, typical ECG changes include concave upward ST-segment elevation, upright T waves in the leads with ST-segment elevation, and PR depression. ECG findings in the setting of myocarditis and pericarditis following COVID-19 vaccination are similar to other causes.
Although not specific to myocarditis, elevated troponin levels, indicating myocyte injury, are almost always present in the setting of acute myocarditis.
The degree of troponin elevation varies and depends the severity of myocardial injury and timing of evaluation in relation to symptom onset. Elevated brain natriuretic peptide (BNP) levels indicate increased ventricular stretch and are elevated in the setting of heart failure. BNP is often assessed in patients with suspected myocarditis when heart failure symptoms are present. However, elevations of BNP are not included in the CDC working case definitions of probable or confirmed acute myocarditis, and values are not consistently evaluated or reported. Other testing, such as acute and convalescent viral testing (eg, SARS-CoV-2, coxsackievirus, and so forth), should be considered when clinically appropriate to exclude other potential causes of myocarditis.
Management
Currently, there are no specific management recommendations for myocarditis following COVID-19 vaccination. Care is largely supportive following guidelines for myocarditis due to other causes.
Treatment is typically focused on addressing potential sequelae such as heart failure or arrhythmia as per guideline-directed medical therapy. For patients with very mild symptoms with rapid improvement, therapy can often be deferred.
Individuals are typically safe to return to their normal daily activities after their symptoms improve. However, the optimal duration of exercise restriction is unknown. The American Heart Association and American College of Cardiology Foundation have recommended 3 to 6 months of restriction from competitive sports following myocarditis. Repeat evaluation of serum biomarkers, 24-hour Holter monitor, and echocardiography is recommended before return to exercise in order to ensure normal ventricular function, resolution of active inflammation, and absence of arrhythmias.
Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the american heart association and american college of cardiology.
Although there is no clear evidence on risk associated with subsequent vaccination, current guidelines suggest that further doses of mRNA COVID-19 vaccines should be deferred among individuals who experienced myocarditis within 6 weeks of receiving a previous dose of an mRNA COVID-19 vaccine.
Myocarditis following COVID-19 vaccination is typically associated with a transient, mild course, with complete resolution of symptoms within 1 to 3 weeks in most of the patients.
Patients with more severe disease with ventricular dysfunction might require hospitalization, although most reports indicate that patients who do require hospitalization typically require a short stay of less than 5 days.
Although most patients with myocarditis after COVID-19 vaccination have a mild course, there are limited long-term follow-up data, given the relatively recent introduction of these vaccines. Improvement or normalization of ejection fraction and resolution of symptoms in nearly all patients with myocarditis following COVID-19 vaccination has been demonstrated at short-interval follow-up.
Limited intermediate term (∼5–6 months) follow-up data have demonstrated normalization of troponin levels, no residual cardiac symptoms or functional impairment, and no adverse cardiac events.
Although these data are reassuring, further studies with long-term clinical and imaging follow-up are needed. Additional study is also needed to determine the risk with subsequent vaccine doses and other potential risk factors including prior history of myocarditis.
Summary
Myocarditis is an established but rare adverse event following administration of mRNA-based COVID-19 vaccines, with highest risk in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment, which is reassuring. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination.
Clinics care points
•
Myocarditis following mRNA-based COVID-19 vaccines is rare; however, adolescent and young adult men are at highest risk.
•
Chest pain is the most common symptom, with typical onset within a few days of vaccine administration.
•
CMR plays an important role in the diagnosis of acute myocarditis following vaccination, with typical findings of subepicardial late gadolinium enhancement and co-localizing edema at the basal inferior lateral wall.
•
The disease course of myocarditis following COVID-19 vaccination is typically transient and mild, with resolution of symptoms within 1 to 3 weeks in most patients.
•
However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination.
Funding
Dr P. Thavendiranathan is supported by a Canada Research Chair. Dr J.A. Udell is supported by a Department of Medicine, University of Toronto Merit Award and receives support from Ontario Ministry of Colleges and Universities Early Researcher Award (ER15-11-037).
Disclosure
Dr K. Hanneman has received speaker’s honorarium from Sanofi-Genzyme, Amicus, and Medscape. Dr P. Thavendiranathan has received speaker’s honorarium from Amgen, Boehringer Ingelheim-Lilly, and Takeda. Dr J.A. Udell has served as a consultant or speaker for AstraZeneca, Bayer, Boehringer Ingelheim-Lilly, Janssen, Merck, Novartis, and Sanofi and has received research grants from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim-Lilly, and Janssen.
References
Hanneman K.
Iwanochko R.M.
Thavendiranathan P.
Evolution of lymphadenopathy at PET/MRI after COVID-19 vaccination.
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the european society of cardiology working group on myocardial and pericardial diseases.
United States Department of Health and Human Services (DHHS)
Public health service (PHS), centers for disease control (CDC)/food and Drug administration (FDA), vaccine adverse event reporting system (VAERS) 1990 - 01/07/2022.
(CDC WONDER On-line Database [cited 2022 January 16]. Available at:)
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, june 2021.
COVID-19 vaccine safety updates: primary series in children and adolescents ages 5–11 and 12–15 years, and booster doses in adolescents ages 16–24 years 2022.
2011 Consensus statement on endomyocardial biopsy from the association for european cardiovascular pathology and the society for cardiovascular pathology.
First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the pfizer-biontech mRNA COVID-19 vaccine (BNT162b2, Comirnaty): an extremely rare idiosyncratic hypersensitivity reaction.
Combined cardiac fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging assessment of myocardial injury in patients who recently recovered from COVID-19.
Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the american heart association and american college of cardiology.
00064-2&id=gr1.jpg){kind=link}
00064-2&id=gr2.jpg){kind=link}
00064-2&id=gr3.jpg){kind=link}
00064-2&id=gr4.jpg){kind=link}